Curated News
By: NewsRamp Editorial Staff
January 26, 2026
Innovotech Seeks U.S. OTCQB Listing to Boost Investor Access and Liquidity
TLDR
- Innovotech's OTCQB listing offers investors early access to a growing Canadian biotech leader, potentially increasing share liquidity and U.S. market exposure.
- Innovotech will list on OTCQB while maintaining its TSXV listing, using foreign issuer exemptions to avoid additional compliance burdens for U.S. trading.
- By expanding access to U.S. investors, Innovotech can accelerate development of its biofilm science technologies that combat antimicrobial resistance globally.
- A Canadian biofilm science company is making its stock available to U.S. investors through the OTCQB market with simplified electronic settlement.
Impact - Why it Matters
This news matters because it signals Innovotech's strategic expansion into the U.S. market, potentially increasing investment opportunities and liquidity for shareholders. For investors, it offers easier access to a company at the forefront of biofilm science and antimicrobial testing, sectors critical to healthcare and pharmaceutical innovation. By enhancing visibility and simplifying trading for U.S. investors, this move could drive growth and foster partnerships, impacting public health through advanced research in infection control and drug development.
Summary
Innovotech Inc., a Canadian contract research organization specializing in advanced laboratory services and proprietary technologies, has announced its intention to secure a stock quotation on the OTCQB venture market in the United States. This strategic move aims to enhance the company's visibility within the U.S. investment community, making it more accessible to both retail and institutional investors while increasing the liquidity of its shares. The OTCQB quotation will operate alongside Innovotech's primary listing on the TSX Venture Exchange in Canada, with the company expecting no significant additional compliance burdens due to its status as a foreign private issuer. Concurrently, Innovotech will apply for eligibility with the Depository Trust Company to facilitate simplified electronic clearing and settlement for U.S. investors, streamlining the trading process.
As a leader in biofilm science, Innovotech provides expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions through its ISO-certified and GMP-accredited facilities. The company's innovative methodologies include the widely-used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing, serving clients across multiple sectors under rigorous regulatory standards such as those of the U.S. Food and Drug Administration and Health Canada. This expansion into the U.S. market underscores Innovotech's growth trajectory and commitment to broadening its investor base, leveraging its established reputation in scientific research and development to attract new capital and partnerships.
The announcement highlights Innovotech's proactive approach to capital markets, aiming to tap into the larger U.S. financial ecosystem without disrupting its core operations. By meeting the OTCQB's financial standards and reporting requirements, the company positions itself as a credible investment opportunity in the biotechnology and healthcare sectors. This development is detailed further in the original release on www.newmediawire.com, where stakeholders can access comprehensive information about Innovotech's strategic initiatives and future prospects in the evolving landscape of contract research and biofilm science.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Innovotech Seeks U.S. OTCQB Listing to Boost Investor Access and Liquidity
